Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million

Reuters03-27

Indaptus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 annual report published; net loss widens to $21 million

Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.
David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.
A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.
The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.
Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622984838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622984838","market":"nz","top_or_hot":-1,"title":"Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 annual report published; net loss widens to $21 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.\n        </li>\n<li>\n          David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.\n        </li>\n<li>\n          A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.\n        </li>\n<li>\n          The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.\n        </li>\n<li>\n          Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndaptus Therapeutics FY2025 annual report published; net loss widens to $21 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 02:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Indaptus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 annual report published; net loss widens to $21 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.\n        </li>\n<li>\n          David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.\n        </li>\n<li>\n          A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.\n        </li>\n<li>\n          The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.\n        </li>\n<li>\n          Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbWWw6h:1","article_id":"2622984838","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622984838","pubTimestamp":1774548653,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INDP":"Indaptus Therapeutics, Inc."},"translate_title":"Indaptus Therapeutics 2025财年年度报告发布；净亏损扩大至2100万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDP":0.9},"content_text":"Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million\n    \n\n\n          Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.\n        \n\n          David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.\n        \n\n          A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.\n        \n\n          The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.\n        \n\n          Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622984838","isCrawlerRequest":true}